Healthcare · NYSE/NASDAQ: TMO
THERMO FISHER SCIENTIFIC INC.
Diagnostics & Research
Market Cap $176.04B
Verdict: Exceptional
Quality Scores
Multi-Bagger
85/100
Compounder Quality
93/100
Management Credibility
92/100
Governance
92/100
Cash Flow Quality
95/100
AI Summary
Thermo Fisher Scientific (TMO) has evolved into a global powerhouse in life sciences, demonstrating a spectacular 10-year transformation from a $4.95B revenue base in 2016 to nearly $45B by 2025. The company's expansion is driven by a masterclass in the 'M&A flywheel' strategy, successfully integrating large-scale acquisitions such as PPD and Life Technologies while maintaining operational discipline. The COVID-19 pandemic provided a massive windfall of cash flow, which management has skillfully recycled into permanent diagnostic and bioprocessing infrastructure. Despite a post-pandemic…
Top Opportunities
- Consistent 10-year Revenue CAGR
- Strong market leader in Life Sciences
- Operational cash flow reliability
Top Risks
- Significant long-term debt burden
- Post-pandemic revenue normalization pressure
- Operating margin contraction (2021-2023)
Latest report: Read the annual report summary →
Unlock the full report
Full sections, financial charts, AI chat and PDF export are available with Premium.